The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists.

The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition. The major changes in the classification and their rationale are presented here.

The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene expression analysis and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added. Therefore, there is a clear need for a revision to the current classification.


In collaboration with the Society for Hematopathology and the European Association for Haematopathology, the World Health Organization (WHO) published the third and fourth editions of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, in 2001 and 2008, respectively, as part of a series of WHO Classification of Tumours “blue book” monographs. In the spring of 2014, a clinical advisory committee (CAC) composed of ∼100 pathologists, hematologists, oncologists, and geneticists from around the world convened to propose revisions to the fourth edition of the classification.

The revision of the fourth edition follows the philosophy of the third and fourth editions to incorporate clinical features, morphology, immunophenotyping, cytogenetics, and molecular genetics to define disease entities of clinical significance. The fourth edition of the classification of hematopoietic and lymphoid tissues was the second volume of the WHO “blue book” tumor series, and the series publication is still in progress. A fifth edition series cannot begin until the fourth edition series is completed; but after 8 years of information and experience that have emerged from scientific and clinical studies, a revision of these criteria for hematopoietic and lymphoid neoplasms was felt to be necessary and timely.

In relation to myeloid neoplasms and acute leukemia, this revision has been influenced by several factors including the following:

  1. The discovery of recently identified molecular features has yielded new perspectives regarding diagnostic and prognostic markers that provide novel insights for the understanding of the pathobiology of these disorders.

  2. Improved characterization and standardization of morphological features aiding in the differentiation of disease groups, particularly of the BCR-ABL1 myeloproliferative neoplasms (MPNs), has increased the reliability and reproducibility of diagnoses.

  3. A number of clinical-pathological studies have now validated the WHO postulate of an integrated approach that includes hematologic, morphologic, cytogenetic, and molecular genetic findings.

For these reasons, the fourth edition is being updated, but this 2016 classification is not a major overhaul of the disease categories. Rather, it is intended to incorporate new knowledge of these disorders obtained since the 2008 publication and is a revision of that classification. The purpose of this report is to summarize the major changes in the revised WHO classification of myeloid neoplasms and acute leukemia and to provide the rationale for those changes. Table 1 lists the major subtypes of myeloid neoplasms and acute leukemias according to the updated (2016) WHO classification.

Table 1

WHO classification of myeloid neoplasms and acute leukemia

Myeloproliferative neoplasms

The categories of MPNs have not significantly changed since the 2008 fourth edition of the classification, but discoveries of new mutations and improved understanding of the morphologic features of some entities have impacted the diagnostic criteria for the disease entities. Mastocytosis, however, is no longer considered a subgroup of the MPNs due to its unique clinical and pathologic features, ranging from indolent cutaneous disease to aggressive systemic disease, and is now a separate disease category in the classification.

With regard to chronic myeloid leukemia (CML), BCR-ABL1+, most cases of CML in chronic phase can be diagnosed from peripheral blood (PB) findings combined with detection of t(9;22)(q34.1;q11.2) or, more specifically, BCR-ABL1 by molecular genetic techniques. However, a bone marrow (BM) aspirate is essential to ensure sufficient material for a complete karyotype and for morphologic evaluation to confirm the phase of disease.1,2 In the era of tyrosine-kinase inhibitor (TKI) therapy, newly diagnosed patients may have a nearly normal lifespan, but regular monitoring for BCR-ABL1 burden and for evidence of genetic evolution and development of resistance to TKI therapy is essential to detect disease progression.3,4

Although the accelerated phase (AP) of CML is becoming less common in the era of TKI therapy, there are no universally accepted criteria for its definition. The criteria for AP in the revised WHO classification include hematologic, morphologic, and cytogenetic parameters which are supplemented by additional parameters usually attributed to genetic evolution,5 and manifested by evidence of resistance to TKIs (see Table 2). These latter “response to TKI therapy” criteria for AP are considered as “provisional” until further supported by additional data. Diagnosis of blast phase (BP) still requires either at least 20% blasts in the blood or BM or the presence of an extramedullary accumulation of blasts. However, because the onset of lymphoid BP may be quite sudden, the detection of any bona fide lymphoblasts in the blood or marrow should raise concern for a possible impending lymphoid BP, and prompt additional laboratory and genetic studies to exclude this possibility.

In recent years, data have emerged that suggest the need for revisions to the diagnostic criteria for the BCR-ABL1 MPNs,6 as many new findings have been demonstrated to have diagnostic and/or prognostic importance:

  1. The discovery of novel molecular findings in addition to JAK2 and MPL mutations, in particular the CALR mutation, provide proof of clonality, diagnostic importance, and influence prognosis.7,8

  2. The CSF3R mutation is strongly associated with chronic neutrophilic leukemia (CNL) (see also “Myelodysplastic/myeloproliferative neoplasms”).9

  3. Polycythemia vera (PV) is possibly underdiagnosed using the hemoglobin levels published in the fourth edition, and the utility of BM morphology as a reproducible criterion for the diagnosis of PV is recognized.8,10,11

  4. It is necessary to differentiate “true” essential thrombocythemia (ET) from prefibrotic/early primary myelofibrosis (prePMF) by, among other features, the morphologic findings in the BM biopsy, including the lack of reticulin fibrosis at onset, and this distinction has prognostic implications.12-14

  5. The minor clinical criteria in prePMF that may have a major impact not only on accurate diagnosis but also on prognosis need to be explicitly defined.14,15

  6. Standardized morphologic criteria of MPNs are important to enhance interobserver reproducibility of morphologic diagnoses (which currently demonstrates consensus rates ranging between 76% and 88%, depending on the study design).12,13,16-18

The revised criteria for CNL, PV, ET, PMF, and prePMF are listed in Tables 3-7 in addition to a slightly modified grading of reticulin and collagen BM fibers (Table 8). It is important to emphasize that an accurate histologic diagnosis has been proven to be key to predict prognosis in this group of diseases.13


As mentioned, mastocytosis is no longer listed under the broad heading of MPNs. Major advances in the understanding of mastocytosis have been made since the 2008 classification,19 and these are incorporated into the text of the monograph. Table 920 lists the 2016 categories of mastocytosis, which includes a shortening of the name of the 2008 category of “systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease (SH-AHNMD)” to the 2016 category of “systemic mastocytosis with an associated hematological neoplasm (SM-AHN).” In many cases, the AHN is an aggressive neoplasm that must be treated and the diagnosis should clearly and separately indicate the presence of this disorder in a distinct diagnosis line.

Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2

The criteria for the diagnosis of the eosinophilia-related proliferations associated with specific molecular genetic changes are retained in the classification, although it is noted that eosinophilia may be absent in a subset cases. In the 2016 revision (Table 10), this disease group will incorporate the myeloid neoplasm with t(8;9)(p22;p24.1);PCM1-JAK2 as a new provisional entity.21,22 This rare entity is characterized by a combination of eosinophilia with BM findings of left-shifted erythroid predominance, lymphoid aggregates, and often myelofibrosis, at times mimicking PMF. It can also rarely present as T- or B-lymphoblastic leukemia (acute lymphoblastic leukemia ALL) and responds to JAK inhibition.23 Other JAK2-rearranged neoplasms, for example, t(9;12)(p24.1;p13.2);ETV6JAK2 and t(9;22)(p24.1;q11.2);BCR-JAK2 may have similar features, but are uncommon and are not currently included as distinct entities. Moreover, ETV6JAK2 and BCR-JAK2–rearranged neoplasms present primarily as B-cell ALL (B-ALL), and these are best considered as BCRABL1–like B-ALL, a new provisional category of B-lymphoblastic leukemia/lymphoma.22

Myelodysplastic/myeloproliferative neoplasms

The myelodysplastic syndrome (MDS)/MPN category was introduced in the third edition to include myeloid neoplasms with clinical, laboratory, and morphologic features that overlap between MDS and MPN.24 Based on accumulated scientific evidence, a provisional entity within the MDS/MPN unclassifiable group, refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T), has been accepted as a full entity, now termed MDS/MPN with ring sideroblasts and thrombocytosis in the 2016 revision. The 2016 revised criteria for diseases in this category are summarized in Tables 11-14.25

In MDS/MPN, the karyotype is often normal or shows abnormalities in common with MDS. Targeted sequencing of genes mutated in myeloid neoplasms detects mutations in a high proportion of cases of chronic myelomonocytic leukemia (CMML) as well as other MDS/MPN patients.26 The most commonly mutated genes in CMML are SRSF2, TET2, and/or ASXL1 (>80% of cases).26,27 Other mutations which occur at lower frequency include SETBP1, NRAS/KRAS, RUNX1, CBL, and EZH2.28,29

They can be helpful adjunct studies in difficult cases, particularly given the frequently normal karyotype of CMML, but should not be used alone as proof of neoplasia because some of these mutations occur in healthy older patients as so-called clonal hematopoiesis of indeterminate potential (CHIP)30,31 (for further discussion, see “Myelodysplastic syndromes”). ASXL1 is a predictor of aggressive disease behavior and has been incorporated into a prognostic scoring system for CMML alongside karyotype and clinicopathologic parameters.27 Of note, NPM1 mutation is seen in a rare subset of CMML (3%-5%) and appears also to herald a more aggressive clinical course.

Chronic myelomonocytic leukemia

A diagnosis of CMML requires both the presence of persistent PB monocytosis ≥1 × 109/L and monocytes accounting for ≥10% of the white blood cell (WBC) differential count. Due to the discovery of molecular and clinical differences between the so-called “proliferative type” of CMML (WBC count ≥13 × 109/L) and the “dysplastic type” (WBC <13 × 109/L), particularly those differences related to aberrancies in the RAS/MAPK signaling pathways,32-34 the separation of CMML into these subtypes is warranted. In addition, blast percentage maintains clear prognostic importance in CMML as initially suggested in the third edition and later confirmed in the fourth edition.

Recent evidence has shown that a more precise prognostication can be obtained with 3 blast-based groupings: CMML-0, a category for cases with <2% blasts in PB and <5% blasts in BM; CMML-1 for cases with 2% to 4% blasts in PB and/or 5% to 9% blasts in BM; and CMML-2 for cases with 5% to 19% blasts in PB, 10% to 19% in BM, and/or when any Auer rods are present.33,35 The revision incorporates the CMML-0 category into the classification scheme. In view of the importance of separating promonocytes (blast equivalent cells) from monocytes, which can have abnormal features in CMML, precise morphologic evaluation is essential, with the appropriate integration of flow cytometry immunophenotyping and cytogenetic and molecular genetic testing. Because other disorders must be excluded before a diagnosis of CMML can be made, BCR-ABL1 rearrangement should be excluded in all cases and PDGFRA, PDGFRB, FGFR1 rearrangements or PCM1JAK2 fusions excluded if eosinophilia is present. A prior well-documented diagnosis of a MPN would also generally exclude CMML or another type of MDS/MPN.36,37

Atypical CML, BCR-ABL1

The rare MDS/MPN subtype atypical CML (aCML) is now better characterized molecularly and can be more easily separated from CNL, a rare subtype of MPN similarly characterized by neutrophilia. Although CNL is strongly associated with the presence of CSF3R mutations, these appear to be very rare in aCML (<10%).38 Conversely, aCML is associated with SETBP1 and/or ETNK1 mutations in up to a third of cases.28,39,40 The so-called MPN-associated driver mutations (JAK2, CALR, MPL) are typically absent in aCML.

Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

The criteria for MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T; previously known as RARS-T) include thrombocytosis (≥450 × 109/L) associated with refractory anemia, dyserythropoiesis in the BM with ring sideroblasts accounting for 15% or more of erythroid precursors, and megakaryocytes with features resembling those in PMF or ET. After the discovery that MDS/MPN-RS-T is frequently associated with mutations in the spliceosome gene SF3B1 (which in turn are associated with the presence of ring sideroblasts), there is now enough evidence to support MDS/MPN-RS-T as a full entity.41-44 In MDS/MPN-RS-T, SF3B1 is often comutated with JAK2 V617F or less frequently (<10%) with CALR, or MPL genes, thus providing a biological explanation for the true hybrid nature of this rare myeloid neoplasm. Unlike MDS with ring sideroblasts (see “Myelodysplastic syndromes”), the number of ring sideroblasts required for a diagnosis of MDS/MPN-RS-T is not altered by the presence or absence of a mutation in SF3B1. Because of changes in the MDS terminology (see “Myelodysplastic syndromes”), the name RARS-T was changed to MDS/MPN-RS-T.

Juvenile myelomonocytic leukemia

Juvenile myelomonocytic leukemia (JMML) is an aggressive clonal hematopoietic disorder of infancy and early childhood characterized by an excessive proliferation of cells of monocytic and granulocytic lineages that is included as a MDS/MPN subtype.45,46 Approximately 90% of patients carry either somatic or germ line mutations of PTPN11, KRAS, NRAS, CBL, or NF1. These genetic aberrations are largely mutually exclusive and activate the RAS/MAPK pathway. The clinical and pathological findings of JMML are not substantially changed from the current WHO fourth edition (2008). However, molecular diagnostic parameters have been refined. The updated diagnostic findings are listed in Table 14.

Myelodysplastic syndromes

The MDS are a group of clonal BM neoplasms characterized by ineffective hematopoiesis, manifested by morphologic dysplasia in hematopoietic cells and by peripheral cytopenia(s). The revised classification introduces refinements in morphologic interpretation and cytopenia assessment and addresses the influence of rapidly accumulating genetic information in MDS diagnosis and classification. Cytopenia is a “sine qua non” for any MDS diagnosis and in prior classifications, MDS nomenclature included references to “cytopenia” or to specific types of cytopenia (eg, “refractory anemia”).

However, the WHO classification relies mainly on the degree of dysplasia and blast percentages for disease classification and specific cytopenias have only minor impact on MDS classification. Moreover, the lineage(s) manifesting significant morphologic dysplasia frequently do not correlate with the specific cytopenia(s) in individual MDS cases.47-49 For these reasons, the terminology for adult MDS has changed to remove terms such as “refractory anemia” and “refractory cytopenia” and replaces them with “myelodysplastic syndrome” followed by the appropriate modifiers: single vs multilineage dysplasia, ring sideroblasts, excess blasts, or the del(5q) cytogenetic abnormality (see Table 15). There are no changes to childhood MDS; refractory cytopenia of childhood remains as a provisional entity within this category.

One of the biggest challenges in this category is separating MDS from reactive causes of cytopenia and dysplasia. Although the threshold to define dysplasia will remain as 10% dysplastic cells in any hematopoietic lineage, it is recognized that dysplasia in excess of 10% may occur in some normal individuals and even more frequently in nonneoplastic causes of cytopenia.50,51 Moreover, identification of dysplasia is not always reproducible among even experienced hematopathologists.52,53 For these reasons, possible reactive etiologies of dysplasia should always be carefully considered prior to making a diagnosis of MDS, particularly when the dysplasia is subtle and limited to 1 lineage. Some dysplastic changes, particularly the presence of micromegakaryocytes (which can be highlighted by immunostaining for megakaryocyte markers in the BM trephine), are relatively specific for myelodysplasia and have high reproducibility.53

The myeloblast percentage, as determined by counting well-prepared, cellular BM aspirate smears and/or touch preparations and a PB smear, remains critical in defining the WHO MDS categories and as risk strata in the Revised International Prognostic Scoring System (IPSS-R).54 The presence of 1% blasts in the PB, with <5% BM blasts, defines 1 type of MDS, unclassifiable (MDS-U). However, because 1% blasts may not be reproducible as a single observation, this finding must now be demonstrated on at least 2 separate occasions in order to diagnose MDS-U according to this criterion. There is a major change in the diagnostic criteria for myeloid neoplasms with erythroid predominance (erythroid precursors ≥50% of all BM cells). In the updated classification, the denominator used for calculating blast percentage in all myeloid neoplasms is all nucleated BM cells, not just the “nonerythroid cells.” This will result in most cases previously diagnosed as the erythroid/myeloid subtype of acute erythroid leukemia now being classified as MDS with excess blasts, as discussed in “AML, not otherwise specified” (see Table 16).

Despite the lowering of the neutropenia prognostic threshold in the IPSS-R to 0.8 × 109/L,54 the WHO thresholds defining cytopenia will remain as in the original IPSS (hemoglobin, <10 g/dL; platelets, <100 × 109/L; absolute neutrophil count, <1.8 × 109/L); a diagnosis of MDS may be made in rare cases with milder levels of cytopenia, but at least 1 cytopenia must be present in order to make the diagnosis. It should be noted that some ethnic groups may have a reference range for normal absolute neutrophil count that is lower than 1.8 × 109/L, and thus caution should be exercised in interpreting neutropenia if it is the only cytopenia. MDS-U will continue to include cases with single lineage dysplasia or isolated del(5q) and pancytopenia, but in such cases all PB counts must be below the WHO thresholds given in this paragraph.

The same cytogenetic abnormalities listed in the 2008 WHO classification55 remain MDS-defining in a cytopenic patient, even in the absence of diagnostic morphologic dysplasia. In such cases, the abnormality must be demonstrated by conventional karyotyping, not by fluorescence in situ hybridization (FISH) or sequencing technologies. The presence of +8, −Y, or del(20q) is not considered to be MDS-defining in the absence of diagnostic morphologic features of MDS. In spite of the increased knowledge of the prognostic importance of genetic findings in MDS, del(5q) remains as the only cytogenetic or molecular genetic abnormality that defines a specific MDS subtype. Based on recent data showing no adverse effect of 1 chromosomal abnormality in addition to the del(5q),56-58 the entity MDS with isolated del(5q) may be diagnosed if there is 1 additional cytogenetic abnormality besides the del(5q), unless that abnormality is monosomy 7 or del(7q). Even though cytogenetic findings are not used to define other specific subtypes of MDS, they are strongly correlated with prognosis, as reflected in the 5 cytogenetic prognostic groups in the IPSS-R scheme54,58; thus, a complete BM karyotype remains a critical test in any newly diagnosed MDS case.

As with all the other myeloid neoplasms, a large amount of data has recently become available on recurring mutations in MDS. Targeted sequencing of a limited number of genes can detect mutations in 80% to 90% of MDS patients; the most commonly mutated genes in MDS are SF3B1, TET2, SRSF2, ASXL1, DNMT3A, RUNX1, U2AF1, TP53, and EZH2.59,60 Importantly, acquired clonal mutations identical to those seen in MDS can occur in the hematopoietic cells of apparently healthy older individuals without MDS, so-called “clonal hematopoiesis of indeterminate potential” (CHIP).30,31,61 Although some patients with CHIP subsequently develop MDS, the natural history of this condition is not yet fully understood; thus, the presence of MDS-associated somatic mutations alone is not considered diagnostic of MDS in this classification, even in a patient with unexplained cytopenia, where these mutations may be commonly found.62 Further study is required to determine the optimal management and monitoring of such patients and to investigate possible links between specific mutations, mutant allele fraction, or mutation combinations and subsequent development of bona fide MDS.63 Rare cases of familial MDS are associated with germ line mutations, which can be investigated by sequencing non-MDS patient tissue.

The number and types of specific mutations are strongly associated with disease outcome in MDS, and the addition of mutation data improves the prognostic value of existing risk-stratification schemes in MDS.64,65TP53 mutation is associated with aggressive disease in MDS in general66 and appears to predict poorer response to lenalidomide in patients with del(5q).67-69 Evaluation for TP53 mutation is recommended in patients with MDS with isolated del(5q) to help identify an adverse prognostic subgroup in this generally favorable prognosis MDS entity.

With regard to MDS with ring sideroblasts (MDS-RS), recurrent mutations in the spliceosome gene SF3B1 are frequent in MDS and are associated with the presence of ring sideroblasts. A change in the classification of MDS is the inclusion now of MDS cases with ring sideroblasts and multilineage dysplasia, lacking excess blasts or an isolated del(5q) abnormality, into the category of MDS-RS. This change is based largely on the link between ring sideroblasts and an SF3B1 mutation, which appears to be an early event in MDS pathogenesis, manifests a distinct gene expression profile, and correlates with a favorable prognosis.42,44,70-72 Recent studies have shown that in cases of MDS with any ring sideroblasts, the actual percentage of ring sideroblasts is not prognostically relevant.73 Thus, in the revised classification, if an SF3B1 mutation is identified, a diagnosis of MDS-RS may be made if ring sideroblasts comprise as few as 5% of nucleated erythroid cells, whereas at least 15% ring sideroblasts are still required in cases lacking a demonstrable SF3B1 mutation. MDS-RS cases will be subdivided into cases with single lineage dysplasia (previously classified as refractory anemia with ring sideroblasts) and cases with multilineage dysplasia (previously classified as refractory cytopenia with multilineage dysplasia). Although MDS-RS cases lacking SF3B1 mutation appear to have an adverse prognosis compared with those with the mutation, the role of multilineage dysplasia vs the SF3B1 mutation in influencing outcome in MDS-RS remains controversial.72,73

Myeloid neoplasms with germ line predisposition

Although most cases of MDS or acute leukemia are sporadic diseases, it is becoming clear that a subgroup of cases is associated with germ line mutations and is familial.74 A major change to the 2016 revision of the WHO classification is the addition of a section on myeloid neoplasms with germ line predisposition, which includes cases of MDS, MDS/MPN, and acute leukemias that occur on the background of a predisposing germ line mutation. The presence of the specific underlying genetic defect or predisposition syndrome should be noted as part of the diagnosis. Of note, germ line genetic aberrations are not unique to the patient with MDS or acute leukemia and should raise awareness of the need to screen family members for these aberrations. The major categories of such familial cases are summarized in Table 17.

AML with recurrent genetic abnormalities

The WHO continues to define specific acute myeloid leukemia (AML) disease entities by focusing on significant cytogenetic and molecular genetic subgroups. A large number of recurring, balanced cytogenetic abnormalities are recognized in AML, and most of those that are not formally recognized by the classification are rare.75 The most common of these rare abnormalities that occur in pediatric patients are summarized in supplemental Table 1 (available on the Blood Web site), but these will not represent new disease categories. Minor refinements related to updates in gene names (such as the change from MLL to KMT2A) are included as well as recognition that the inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) does not represent a fusion gene, but repositions a distal GATA2 enhancer to activate MECOM expression and simultaneously confer GATA2 haploinsufficiency.76,77 In order to stress the significance of the PMLRARA fusion, which may be cryptic or result from complex cytogenetic rearrangements other than t(15;17)(q24.1;q21.2), acute promyelocytic leukemia (APL) with this fusion is renamed as APL with PML-RARA. Finally, a new provisional category of AML with BCR-ABL1 is added to recognize these rare de novo AML cases that may benefit from TKI therapy.78,79 Although the diagnostic distinction between de novo AML with BCR-ABL1 and blast transformation of CML may be difficult without adequate clinical information, the significance of detecting this targetable fusion is felt to warrant a provisional disease category. Preliminary data suggest that deletion of antigen receptor genes (IGH, TCR), IKZF1 and/or CDKN2A may support a diagnosis of de novo disease vs BP of CML.80

Although the WHO authors struggled with how to incorporate the recent discoveries in gene mutations in AML,81-83 the text for all disease categories is expanded to discuss the prognostic significance of various gene mutations and their frequency in the different AML subtypes. An updated table further summarizes the various genes mutated in AML and their significance (supplemental Table 2). The finding that the improved prognosis associated with AML with mutated CEBPA is associated with biallelic, but not single, mutations of the gene84-88 has resulted in a change in that disease definition to require biallelic mutations. Additionally, due to the lack of prognostic significance of multilineage dysplasia in patients without MDS-associated cytogenetic findings and with a mutation of NPM1 or biallelic mutation of CEBPA,89-91 these mutations now supersede the presence of multilineage dysplasia in the classification. Finally, a provisional category of AML with mutated RUNX1 has been added to the classification for cases of de novo AML with this mutation that are not associated with MDS-related cytogenetic abnormalities. This new provisional disease category appears to represent a biologically distinct group with a possibly worse prognosis than other AML types.92-95

AML with myelodysplasia-related changes

The category of AML with myelodysplasia-related changes has been retained, but is refined to better incorporate cases with features suggesting a poor prognosis. As mentioned, the presence of multilineage dysplasia alone will not classify a case as AML with myelodysplasia-related changes when a mutation of NPM1 or biallelic mutation of CEBPA is present.89-91 In cases lacking these mutations, the morphologic detection of multilineage dysplasia (defined as the presence of 50% or more dysplastic cells in at least 2 cell lines) remains a poor prognostic indicator and is sufficient to make a diagnosis of AML with myelodysplasia-related changes.90,96,97 A history of MDS remains as an inclusion criterion for this category as does the presence of an MDS-related cytogenetic abnormality with 1 exception: del(9q) has been removed as a defining cytogenetic abnormality for AML with myelodysplasia-related changes because of its association with NPM1 or biallelic CEBPA mutations98,99 and its apparent lack of prognostic significance in those settings. Table 18 lists the cytogenetic abnormalities that now define AML with myelodysplasia-related changes.

Therapy-related myeloid neoplasms

Therapy-related myeloid neoplasms (t-MNs) remain as a distinct category in the classification for patients who develop myeloid neoplasms following cytotoxic therapy. The t-MNs may be further subdivided as therapy-related MDS or AML (t-MDS or t-AML), but the associated cytogenetic abnormality, which is important for determining therapy and prognosis, should be identified in the final diagnosis. A number of t-MN cases have been shown to have germ line mutations in cancer susceptibility genes; careful family histories to uncover cancer susceptibility are warranted in t-MN patients.100

AML, not otherwise specified

Although the subcategories of AML, not otherwise specified (NOS) lack prognostic significance when cases are classified based on NPM1 mutation and CEBPA biallelic mutation status,101 the CAC agreed to keep the AML, NOS subcategories with only a single change: the subcategory of acute erythroid leukemia, erythroid/myeloid type (previously defined as a case with ≥50% BM erythroid precursors and ≥20% myeloblasts among nonerythroid cells) has been removed from the AML category. In the new classification, myeloblasts are always counted as a percentage of total marrow cells and the majority of such cases have <20% total blast cells and are now classified as MDS (usually MDS with excess blasts). This change was based on the close biologic relationship of erythroid/myeloid type acute erythroid leukemia to MDS in terms of its clinical presentation, morphologic features, and genetic abnormalities, as well as the low reproducibility of nonerythroid blast counts and an attempt to achieve uniformity in expressing blast percentages across all myeloid neoplasms.102-106 Cases with ≥50% or more erythroid cells and ≥20% total myeloblasts usually meet criteria for AML with myelodysplasia-related changes and should be diagnosed as such; cases with ≥20% total myeloblasts not meeting criteria for AML with myelodysplasia-related changes or AML with recurrent genetic abnormalities should be categorized as 1 of the other subtypes of AML, NOS. Pure erythroid leukemia remains as an AML, NOS subtype and is now the only type of acute erythroid leukemia. Table 16 summarizes the current diagnostic approach to neoplastic marrow specimens with 50% or more erythroid precursors.

Myeloid sarcoma

Myeloid sarcoma remains in the classification as a unique clinical presentation of any subtype of AML. Myeloid sarcoma may present de novo, may accompany PB and marrow involvement, may present as relapse of AML, or may present as progression of a prior MDS, MPN, or MDS/MPN.107 Although listed separately in the classification, cases of myeloid sarcoma without evidence of marrow disease should be investigated comprehensively so that they can be classified into a more specific AML subtype.

Myeloid proliferations of Down syndrome

The myeloid proliferations of Down syndrome include transient abnormal myelopoiesis (TAM) and myeloid leukemia associated with Down syndrome.108,109 Both are usually megakaryoblastic proliferations, with TAM occurring at birth or within days of birth and resolving in 1 to 2 months and myeloid leukemia occurring later, but usually in the first 3 years of life with or without prior TAM and persisting if not treated. The myeloid neoplasms of Down syndrome have a similar behavior that is independent of blast cell count and these are not subclassified into MDS or AML. Both TAM and myeloid leukemia associated with Down syndrome are characterized by GATA1 mutations and mutations of the JAK-STAT pathway, with additional mutations identified in the myeloid leukemia cases.110

Acute leukemias of ambiguous lineage

No new entities will be defined within this subgroup of acute leukemias. However, several studies have been published since the 2008 classification that have confirmed both the clinical relevance of the entity and its subdivision into genetic subgroups.111,112 Although data are still preliminary, it appears that mixed phenotype acute leukemia (MPAL) with the t(9;22) can respond favorably to treatment that includes a TKI.113,114

The small list of specific lineage markers useful for defining MPAL is unchanged (Table 19), but it is now emphasized that in cases in which it is possible to resolve 2 distinct blast populations, it is not necessary that the specific markers be present, but only that each individual population would meet a definition for either a B, T, or myeloid leukemia. Similarly, cases of ALL or AML in which a diagnosis of MPAL is not being considered do not need to meet the more strict MPAL criteria in order to assign lineage; these criteria do not universally apply for the diagnosis of AML or ALL, but only for MPAL. It is also now recognized that some cases of otherwise typical B-ALL with homogeneous expression of lymphoid markers on a single blast population may express low-level myeloperoxidase using immunophenotypic methods without other evidence of myeloid differentiation. Because the clinical significance of this finding has not yet been established, it is recommended that care be taken before making a diagnosis of B/myeloid MPAL when low-intensity myeloperoxidase (MPO) is the only myeloid-associated feature. Multiparameter flow cytometry is the method of choice for recognizing MPAL; even when there are not 2 distinctly separable populations, most cases of MPAL will show heterogeneity of expression of some antigens such that MPO expression will be expressed on the subset of blasts that show relatively brighter expression of myeloid markers and lower intensity of B-cell–associated markers.

B-cell lymphoblastic leukemia/lymphoma (B-ALL)

Two important new provisional entities with recurrent genetic abnormalities have been recognized and incorporated into the classification and these are discussed in more detail in the following sections. In addition, the classification of hypodiploid B-ALL now highlights the unique association between low hypodiploid ALL and TP53 mutations that are often constitutional.115,116

B-ALL with intrachromosomal amplification of chromosome 21.

This leukemia is characterized by amplification of a portion of chromosome 21, characteristically detected by FISH with a probe for the RUNX1 gene that reveals 5 or more copies of the gene (or 3 or more extra copies on a single abnormal chromosome 21 in metaphase FISH).117,118 It occurs in about 2% of children with ALL, especially older children with low WBC counts. It is uncommon in adults. This new entity is associated with an adverse prognosis which can, to some extent, be overcome with more aggressive therapy.117

B-ALL with translocations involving tyrosine kinases or cytokine receptors (“BCR-ABL1–like ALL”).

This newly recognized entity is assuming increasing importance because of its association with an adverse prognosis and responses of some cases to TKI therapies; however, it has been difficult to define in the clinical setting. It was originally described separately by different groups who demonstrated a series of cases of poor-prognosis childhood ALL with gene expression profiles similar to those seen in cases of ALL with BCRABL1,119,120 though different algorithms applied to the same sets of cases did not classify all cases the same way.121 Common features of BCRABL1–like ALL include translocations involving other tyrosine kinases, or alternatively translocations involving either the cytokine receptor-like factor 2 (CRLF2) or, less commonly, rearrangements leading to truncation and activation of the erythropoietin receptor (EPOR).122 Cases with CRLF2 translocations are often associated with JAK gene mutations and are particularly common in children with Down syndrome.123 This translocation results in upregulation of the thymocyte stromal lymphopoietin receptor (TSLPR) gene product of CRLF2 on leukemic cells that can readily be detected by flow cytometry.

The cases with translocations involving tyrosine kinase genes involve many different genes including ABL1 (with partners other than BCR), as well as other kinases including ABL2, PDGFRB, NTRK3, TYK2, CSF1R, and JAK2.124 Over 30 different partner genes have been described. Some patients, especially those with EBF1PDGFRB translocations, have shown remarkable responses to TKI therapy, even after failing conventional therapy.125

Patients with BCRABL1–like ALL show a high frequency of loss of IKZF1 and CDKN2A/B, but these deletions also occur in high frequency in other types of ALL as well.121

T-cell lymphoblastic leukemia/lymphoma (T-ALL)

Although there has been considerable investigation into genetic mechanisms of T-cell ALL (T-ALL) over the past decade, with the ability to identify nonoverlapping genetic subgroups of T-ALL that can, to some extent, be matched to stages of differentiation,126 assays to measure these are not yet standard and the prognostic implications still controversial; thus, most differentiation stage subgroups are not formally included in the classification. However, 1 subset with unique biology is recognized as a new provisional entity (see next paragraph). Indolent T-lymphoblastic proliferation, which was briefly mentioned in the fourth edition classification, is now a more readily recognized nonneoplastic entity that may mimic T-lymphoblastic lymphoma.127 It typically involves lymphoid tissue of the upper aerodigestive tract but may occur in other locations. Local recurrences are common and systemic dissemination is rare. Histologic examination of involved lymph nodes shows infiltration and sometimes replacement by proliferations of lymphoblasts that are less cytologically atypical than the usual T-lymphoblastic lymphoma. Although the blasts have an immature thymic phenotype that can be demonstrated by TdT staining in lymph nodes, the phenotype reflects a developmentally normal, nonaberrant phenotype and the proliferations are not clonal. These latter features allow this indolent entity to be distinguished from T-lymphoblastic lymphoma.

Early T-precursor (ETP) ALL leukemia has a unique immunophenotypic and genetic makeup indicating only limited early T-cell differentiation, with retention of some myeloid and stem cell characteristics at both the immunophenotypic and genetic level.128-131 By definition, blasts in ETP ALL express CD7 but lack CD1a and CD8, and are positive for 1 or more of the myeloid/stem cell markers CD34, CD117, HLADR, CD13, CD33, CD11b, or CD65.128 They typically also express CD2 and cytoplasmic CD3 and may express CD4, but these are not part of the definition. CD5 is often negative and when positive is present on <75% of the blast population. Myeloid-associated gene mutations, such as FLT3, NRAS/KRAS, DNMT3A, IDH1, and IDH2, are reported at high frequency in ETP ALL,129,130 whereas more typical T-ALL–associated mutations such as activating mutations in NOTCH1 or mutations in CDKN1/2 are infrequent.131 Although initial small series of ETP ALL suggested that outcome was very poor,128,132 more recent larger series with more effective therapy showed either a small but statistically nonsignificant difference in outcome,133 or, in the largest series to date, no prognostic significance.134


Contribution: All authors were involved in the writing and editing of the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Daniel A. Arber, Department of Pathology, Stanford University, 300 Pasteur Dr H1401 M/C 5627, Stanford, CA 94305; e-mail: darber{at}stanford.edu.


This work was supported by the Clinical Advisory Committee meeting (Chicago, IL, March 31-April 1, 2014) from the following organizations: American Society of Hematology, Joseph Carreras Foundation, Fondazione Italiana Linfomi (FIL), Leukemia Clinical Research Foundation, University of Chicago Comprehensive Cancer Center, Beckman Coulter Corporation, Celgene Corporation, Dako, Genentech Corporation, Incyte Corporation, Leica Corporation, Millennium Pharmaceuticals, Pharmacyclics, Seattle Genetics Corporation, Sysmex Corporation, and Ventana Medical Systems, Inc, a member of the Roche Group.

2 thoughts on “The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

  1. This web page can be a walk-by way of for all the data you needed about this and didn抰 know who to ask. Glimpse right here, and also you抣l definitely uncover it.

  2. Interesting theme, I will take part. Together we can come to a right answer.

Leave a Reply

Your email address will not be published. Required fields are marked *